Researchers from the University of Liverpool presented data this week evaluating the use of nanotechnology to improve drug therapies for HIV patients. The team touted its data at the Conference on Retroviruses and Opportunistic Infections in Seattle.
The trial enrolled healthy patients and evaluated the use of orally-dosed solid drug nanoparticles to optimize HIV therapy, according to lead researchers Andrew Owen and Steve Rannard.
The results demonstrated that the solid drug nanoparticles can cut the therapy dose of 2 drugs, efavirenz and lopinavir, by 50%, while maintaining therapeutic exposure.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Nanotechnology could cut dose of HIV treatment in half appeared first on MassDevice.
from MassDevice http://ift.tt/2lMuxDP
Cap comentari:
Publica un comentari a l'entrada